Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Dibigatran Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Pradaxa
  • 1.3.3 Pradax
  • 1.3.4 Prazaxa
• 1.4 Market Segment by Application
  • 1.4.1 Global Dibigatran Market Share by Application (2019-2025)
  • 1.4.2 stroke
  • 1.4.3 deep vein thrombosis
  • 1.4.4 pulmonary embolism
  • 1.4.5 systemic embolism
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Dibigatran Market Size
  • 2.1.1 Global Dibigatran Revenue 2014-2025
  • 2.1.2 Global Dibigatran Sales 2014-2025
• 2.2 Dibigatran Growth Rate by Regions
  • 2.2.1 Global Dibigatran Sales by Regions 2014-2019
  • 2.2.2 Global Dibigatran Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Dibigatran Sales by Manufacturers
  • 3.1.1 Dibigatran Sales by Manufacturers 2014-2019
  • 3.1.2 Dibigatran Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Dibigatran Revenue by Manufacturers (2014-2019)
  • 3.2.2 Dibigatran Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Dibigatran Market Concentration Ratio (CR5 and HHI)
• 3.3 Dibigatran Price by Manufacturers
• 3.4 Key Manufacturers Dibigatran Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Dibigatran Market
• 3.6 Key Manufacturers Dibigatran Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Pradaxa Sales and Revenue (2014-2019)
  • 4.1.2 Pradax Sales and Revenue (2014-2019)
  • 4.1.3 Prazaxa Sales and Revenue (2014-2019)
• 4.2 Global Dibigatran Sales Market Share by Type
• 4.3 Global Dibigatran Revenue Market Share by Type
• 4.4 Dibigatran Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Dibigatran Sales by Application

6 United States

• 6.1 United States Dibigatran Breakdown Data by Company
• 6.2 United States Dibigatran Breakdown Data by Type
• 6.3 United States Dibigatran Breakdown Data by Application

7 European Union

• 7.1 European Union Dibigatran Breakdown Data by Company
• 7.2 European Union Dibigatran Breakdown Data by Type
• 7.3 European Union Dibigatran Breakdown Data by Application

8 China

• 8.1 China Dibigatran Breakdown Data by Company
• 8.2 China Dibigatran Breakdown Data by Type
• 8.3 China Dibigatran Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Dibigatran Breakdown Data by Company
• 9.2 Rest of World Dibigatran Breakdown Data by Type
• 9.3 Rest of World Dibigatran Breakdown Data by Application
• 9.4 Rest of World Dibigatran Breakdown Data by Countries
  • 9.4.1 Rest of World Dibigatran Sales by Countries
  • 9.4.2 Rest of World Dibigatran Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Pfizer, Inc. (US)
  • 10.1.1 Pfizer, Inc. (US) Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Dibigatran
  • 10.1.4 Dibigatran Product Introduction
  • 10.1.5 Pfizer, Inc. (US) Recent Development
• 10.2 Bayer Healthcare AG (Germany)
  • 10.2.1 Bayer Healthcare AG (Germany) Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Dibigatran
  • 10.2.4 Dibigatran Product Introduction
  • 10.2.5 Bayer Healthcare AG (Germany) Recent Development
• 10.3 GlaxoSmithKline Plc. (UK)
  • 10.3.1 GlaxoSmithKline Plc. (UK) Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Dibigatran
  • 10.3.4 Dibigatran Product Introduction
  • 10.3.5 GlaxoSmithKline Plc. (UK) Recent Development
• 10.4 Boehringer Ingelheim (Germany)
  • 10.4.1 Boehringer Ingelheim (Germany) Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Dibigatran
  • 10.4.4 Dibigatran Product Introduction
  • 10.4.5 Boehringer Ingelheim (Germany) Recent Development
• 10.5 Sanofi S.A. (France)
  • 10.5.1 Sanofi S.A. (France) Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Dibigatran
  • 10.5.4 Dibigatran Product Introduction
  • 10.5.5 Sanofi S.A. (France) Recent Development
• 10.6 Abbott India Limited (India)
  • 10.6.1 Abbott India Limited (India) Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Dibigatran
  • 10.6.4 Dibigatran Product Introduction
  • 10.6.5 Abbott India Limited (India) Recent Development
• 10.7 Aspen Holdings (South Africa)
  • 10.7.1 Aspen Holdings (South Africa) Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Dibigatran
  • 10.7.4 Dibigatran Product Introduction
  • 10.7.5 Aspen Holdings (South Africa) Recent Development
• 10.8 Bristol-Myers Squibb Company (US)
  • 10.8.1 Bristol-Myers Squibb Company (US) Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Dibigatran
  • 10.8.4 Dibigatran Product Introduction
  • 10.8.5 Bristol-Myers Squibb Company (US) Recent Development
• 10.9 Eisai Inc. (US)
  • 10.9.1 Eisai Inc. (US) Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Dibigatran
  • 10.9.4 Dibigatran Product Introduction
  • 10.9.5 Eisai Inc. (US) Recent Development
• 10.10 Mitsubishi Tanabe Pharma Corporation (Japan)
  • 10.10.1 Mitsubishi Tanabe Pharma Corporation (Japan) Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Dibigatran
  • 10.10.4 Dibigatran Product Introduction
  • 10.10.5 Mitsubishi Tanabe Pharma Corporation (Japan) Recent Development
• 10.11 Teva Pharmaceutical Industries Ltd. (Israel)

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Dibigatran Sales Channels
  • 11.2.2 Dibigatran Distributors
• 11.3 Dibigatran Customers

12 Market Forecast

• 12.1 Global Dibigatran Sales and Revenue Forecast 2019-2025
• 12.2 Global Dibigatran Sales Forecast by Type
• 12.3 Global Dibigatran Sales Forecast by Application
• 12.4 Dibigatran Forecast by Regions
  • 12.4.1 Global Dibigatran Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Dibigatran Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

In 2019, the market size of Dibigatran is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Dibigatran.

This report studies the global market size of Dibigatran, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Dibigatran sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Pfizer, Inc. (US)
Bayer Healthcare AG (Germany)
GlaxoSmithKline Plc. (UK)
Boehringer Ingelheim (Germany)
Sanofi S.A. (France)
Abbott India Limited (India)
Aspen Holdings (South Africa)
Bristol-Myers Squibb Company (US)
Eisai Inc. (US)
Mitsubishi Tanabe Pharma Corporation (Japan)
Teva Pharmaceutical Industries Ltd. (Israel)

Market Segment by Product Type
Pradaxa
Pradax
Prazaxa

Market Segment by Application
stroke
deep vein thrombosis
pulmonary embolism
systemic embolism

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Dibigatran status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Dibigatran manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Dibigatran are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025